Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi
Status:
Unknown status
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
The study should create data for the selection of a clinically relevant primary endpoint to
assess the efficacy and safety of Buparid/PARI SINUS as compared to Budes Nasal Spray in the
therapy of chronic rhinosinusitis (CRS) with polyposis nasi in adult patients. Ideally, the
selected parameter should allow a correlation between an objective methodology and the
clinical outcome of the study patients.